Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Analysts

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Precigen, Inc. (NASDAQ:PGEN - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $8.25.

A number of research firms have issued reports on PGEN. Citigroup reissued an "outperform" rating on shares of Precigen in a research report on Tuesday, August 19th. Cantor Fitzgerald reissued an "overweight" rating on shares of Precigen in a research report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and set a $8.50 price target on shares of Precigen in a research report on Tuesday, August 19th. Wall Street Zen raised Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. Finally, JPMorgan Chase & Co. upgraded Precigen from an "underweight" rating to a "neutral" rating in a research note on Friday, August 15th.

Institutional Trading of Precigen

Several large investors have recently bought and sold shares of PGEN. Geode Capital Management LLC grew its position in Precigen by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company's stock valued at $3,696,000 after acquiring an additional 53,343 shares in the last quarter. Wells Fargo & Company MN grew its position in Precigen by 12.0% in the fourth quarter. Wells Fargo & Company MN now owns 114,558 shares of the biotechnology company's stock valued at $128,000 after acquiring an additional 12,285 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Precigen by 29.0% in the fourth quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 5,915 shares in the last quarter. Invesco Ltd. grew its position in Precigen by 14.6% in the fourth quarter. Invesco Ltd. now owns 47,307 shares of the biotechnology company's stock valued at $53,000 after acquiring an additional 6,040 shares in the last quarter. Finally, Barclays PLC grew its position in Precigen by 28.3% in the fourth quarter. Barclays PLC now owns 242,899 shares of the biotechnology company's stock valued at $272,000 after acquiring an additional 53,546 shares in the last quarter. Institutional investors and hedge funds own 33.51% of the company's stock.

Precigen Price Performance

PGEN stock traded up $0.54 during trading on Tuesday, reaching $4.18. 24,184,755 shares of the stock traded hands, compared to its average volume of 14,296,194. The business's 50 day moving average price is $1.87 and its 200-day moving average price is $1.67. Precigen has a 52-week low of $0.65 and a 52-week high of $4.21. The firm has a market capitalization of $1.25 billion, a PE ratio of -9.95 and a beta of 1.87.

Precigen (NASDAQ:PGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.The firm had revenue of $0.86 million during the quarter, compared to the consensus estimate of $0.67 million. On average, equities research analysts predict that Precigen will post -0.32 earnings per share for the current year.

Precigen Company Profile

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.